LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $219.00 In stock
10 mg $337.00 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E7556

    Etodolac

    NSAID; TRPA1 agonist, COX-2 inhibitor.

    ≥98%
  • P6801

    Pravastatin Sodium

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • A5035

    5-Aminosalicylic Acid

    Salicylic acid derivative; PPARγ agonist, pote...

    ≥98%
  • E2002

    Efaroxan Hydrochloride

    α2-adrenergic and imidazoline-1 antagonist, AT...

    ≥99%
  • C000082

    C-82

    beta-catenin inhibitor

    ≥99%
  • A1017

    Aceclofenac

    Diclofenac analog, NSAID; COX-2 inhibitor.

    ≥98%
  • L0362

    Lapatinib free base

    Inhibitor of EGFR/HER2 (ErbB2).

    ≥99%
  • N3474

    Nisoldipine

    Calcium channel blocker.

    ≥98%
  • A745817

    Asunaprevir

    Antiviral againt SARS-CoV-2

    ≥98%
  • D3227

    Dihydromethysticin

    Kavalactone originally found in Piper methystic...

    ≥97%
  • P005095

    N-Debenzoylpaclitaxel

    Paclitaxel derivative

    ≥95%
  • B3472

    4,4′-(1,1′-Biphenyl-4,4′-diyldioxy)dianiline

    Potential VEGFR2, Met, RET, Axl, Ron, PDGFR, FG...

    ≥98%
  • A0933

    Acitretin

    Retinoid; RARα/β/γ agonist.

    ≥98%, multiple isomers
  • V0045

    Valacyclovir Hydrochloride

    Neuraminidase inhibitor.

    ≥98%
  • G1310

    GDC-0349

    mTOR inhibitor.

    ≥98%
  • N0161

    β-Naphthoflavone

    AhR agonist.

    ≥98%
  • E5211

    Endomorphin-2

    Endogenous opioid peptide; μOR agonist.

    ≥95%
  • T5968

    Torsemide

    Loop diuretic; NKCC symporter and HSP90 inhibit...

    ≥99%
  • P6264

    PPQ-102

    Pyramido-pyrrolo-quinoxalinedione; CFTR blocker...

    ≥98%
  • R2512

    RGD

    Tripeptide, binds cell surface integrins.

    ≥95%